Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier oncology group GI06-101

Oncologist

Volumn 17, Issue 1, 2012, Pages 13-

  Gabriela Chiorean, E ^a   Ramasubbaiah, Rashmi ^a   Yu, Menggang ^b   Picus, Joel ^c   Bufill, Jose A ^d   Tong, Yan ^b   Coleman, Nicki ^a   Johnston, Erica L ^a   Currie, Colleen ^e   Loehrer, Patrick J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d Northern Indiana Cancer Center   (United States)

^e Hoosier Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; UVOMORULIN;

AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FATIGUE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CADHERINS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; TAXOIDS;

EID: 84856294957     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0253     Document Type: Article

References (0)